Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer

Advances in Pharmacology

Volumn 74, Issue , 2015, Pages 263-302

  Li, Tiangang ^a   Apte, Udayan ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cholestasis; Cytochrome P450; Liver cancer; Liver regeneration; Nuclear receptor

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; COLECALCIFEROL RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; PREGNANE X RECEPTOR;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; BIOTRANSFORMATION; CARCINOGENESIS; CHOLESTASIS; DETOXIFICATION; ENTEROHEPATIC CIRCULATION; GENETIC DISORDER; INFLAMMATION; INTESTINE; LIVER INJURY; LIVER REGENERATION; NEOPLASM; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS; HUMANS; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84929938016     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2015.04.003     Document Type: Chapter

References (188)

1. Ajouz H., Mukherji D., Shamseddine A. Secondary bile acids: An underrecognized cause of colon cancer. World Journal of Surgical Oncology 2014, 12:164.
2. Alemi F., Kwon E., Poole D.P., Lieu T., Lyo V., Cattaruzza F., et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. The Journal of Clinical Investigation 2013, 123:1513-1530.
3. Ali A.H., Carey E.J., Lindor K.D. Recent advances in the development of farnesoid X receptor agonists. Annals of Translational Medicine 2015, 3:5.
4. Allen K., Jaeschke H., Copple B.L. Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. The American Journal of Pathology 2011, 178:175-186.
5. Anakk S., Watanabe M., Ochsner S.A., McKenna N.J., Finegold M.J., Moore D.D. Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis. The Journal of Clinical Investigation 2011, 121:86-95.
6. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. The Journal of Biological Chemistry 2001, 276:28857-28865.
7. Ananthanarayanan M., von Dippe P., Levy D. Identification of the hepatocyte Na+-dependent bile acid transport protein using monoclonal antibodies. The Journal of Biological Chemistry 1988, 263:8338-8343.
8. Araya Z., Wikvall K. 6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochimica et Biophysica Acta 1999, 1438:47-54.
9. Axelson M., Mork B., Sjovall J. Occurrence of 3 beta-hydroxy-5-cholestenoic acid, 3 beta,7 alpha-dihydroxy-5-cholestenoic acid, and 7 alpha-hydroxy-3-oxo-4-cholestenoic acid as normal constituents in human blood. The Journal of Lipid Research 1988, 29:629-641.
10. Baghdasaryan A., Claudel T., Gumhold J., Silbert D., Adorini L., Roda A., et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology 2011, 54:1303-1312.
11. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., et al. OSTalpha-OSTbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005, 42:1270-1279.
12. Barbier O., Torra I.P., Sirvent A., Claudel T., Blanquart C., Duran-Sandoval D., et al. FXR induces the UGT2B4 enzyme in hepatocytes: A potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003, 124:1926-1940.
13. Beilke L.D., Aleksunes L.M., Holland R.D., Besselsen D.G., Beger R.D., Klaassen C.D., et al. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metabolism and Disposition 2009, 37:1035-1045.
14. Belanger A., Pelletier G., Labrie F., Barbier O., Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends in Endocrinology and Metabolism 2003, 14:473-479.
15. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
16. Bhalla S., Ozalp C., Fang S., Xiang L., Kemper J.K. Ligand-activated PXR interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha: Functional implications in hepatic cholesterol and glucose metabolism. The Journal of Biological Chemistry 2004, 279:45139-45147.
17. Bishop-Bailey D., Walsh D.T., Warner T.D. Expression and activation of the farnesoid X receptor in the vasculature. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:3668-3673.
18. Bjorkhem I., Einarsson K., Melone P., Hylemon P. Mechanism of intestinal formation of deoxycholic acid from cholic acid in humans: Evidence for a 3-oxo-delta 4-steroid intermediate. The Journal of Lipid Research 1989, 30:1033-1039.
19. Bodin K., Lindbom U., Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochimica et Biophysica Acta 2005, 1687:84-93.
20. Borude P., Edwards G., Walesky C., Li F., Ma X., Kong B., et al. Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology 2012, 56:2344-2352.
21. Boyer J.L. Bile formation and secretion. Comprehensive Physiology 2013, 3:1035-1078.
22. Boyer J.L., Trauner M., Mennone A., Soroka C.J., Cai S.Y., Moustafa T., et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006, 290:G1124-G1130.
23. Changbumrung S., Tungtrongchitr R., Migasena P., Chamroenngan S. Serum unconjugated primary and secondary bile acids in patients with cholangiocarcinoma and hepatocellular carcinoma. Journal of the Medical Association of Thailand=Chotmaihet thangphaet 1990, 73:81-90.
24. Chatterjee B., Echchgadda I., Song C.S. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods in Enzymology 2005, 400:165-191.
25. Chen X., Chen F., Liu S., Glaeser H., Dawson P.A., Hofmann A.F., et al. Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor. Molecular Pharmacology 2006, 69:1913-1923.
26. Chen W., Chiang J.Y. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 2003, 313:71-82.
27. Chen F., Ma L., Dawson P.A., Sinal C.J., Sehayek E., Gonzalez F.J., et al. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. The Journal of Biological Chemistry 2003, 278:19909-19916.
28. Chen J., Zhao K.N., Chen C. The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Annals of Translational Medicine 2014, 2:7.
29. Chiang J.Y. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. American Journal of Physiology. Gastrointestinal and Liver Physiology 2003, 284:G349-G356.
30. Chiang J.Y. Bile acids: Regulation of synthesis. The Journal of Lipid Research 2009, 50:1955-1966.
31. Childs S., Yeh R.L., Georges E., Ling V. Identification of a sister gene to P-glycoprotein. Cancer Research 1995, 55:2029-2034.
32. Chow E.C., Magomedova L., Quach H.P., Patel R.H., Durk M.R., Fan J., et al. Vitamin D receptor activation down-regulates small heterodimer partner and increases CYP7A1 to lower cholesterol. Gastroenterology 2013, 146:1048-1059.
33. Cipriani S., Mencarelli A., Chini M.G., Distrutti E., Renga B., Bifulco G., et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One 2011, 6:e25637.
34. Cui Y.J., Aleksunes L.M., Tanaka Y., Goedken M.J., Klaassen C.D. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicological Sciences: An Official Journal of the Society of Toxicology 2009, 110:47-60.
35. Denson L.A., Sturm E., Echevarria W., Zimmerman T.L., Makishima M., Mangelsdorf D.J., et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001, 121:140-147.
36. Drocourt L., Ourlin J.C., Pascussi J.M., Maurel P., Vilarem M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. The Journal of Biological Chemistry 2002, 277:25125-25132.
37. Dyson J.K., Hirschfield G.M., Adams D.H., Beuers U., Mann D.A., Lindor K.D., et al. Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews. Gastroenterology & Hepatology 2015, 12:147-158.
38. Eaton J.E., Talwalkar J.A., Lazaridis K.N., Gores G.J., Lindor K.D. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013, 145:521-536.
39. El-Mir M.Y., Badia M.D., Luengo N., Monte M.J., Marin J.J. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science 2001, 100:499-508.
40. Erickson S.K., Lear S.R., Deane S., Dubrac S., Huling S.L., Nguyen L., et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. The Journal of Lipid Research 2003, 44:1001-1009.
41. Fan M., Wang X., Xu G., Yan Q., Huang W. Bile acid signaling and liver regeneration. Biochimica et Biophysica Acta 2015, 1849:196-200.
42. Fiorucci S., Clerici C., Antonelli E., Orlandi S., Goodwin B., Sadeghpour B.M., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. The Journal of Pharmacology and Experimental Therapeutics 2005, 313:604-612.
43. Frankenberg T., Rao A., Chen F., Haywood J., Shneider B.L., Dawson P.A. Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006, 290:G912-G922.
44. Fretland A.J., Omiecinski C.J. Epoxide hydrolases: Biochemistry and molecular biology. Chemico-Biological Interactions 2000, 129:41-59.
45. Gadaleta R.M., van Erpecum K.J., Oldenburg B., Willemsen E.C., Renooij W., Murzilli S., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60:463-472.
46. Gall W.E., Zawada G., Mojarrabi B., Tephly T.R., Green M.D., Coffman B.L., et al. Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. The Journal of Steroid Biochemistry and Molecular Biology 1999, 70:101-108.
47. Goetz R., Beenken A., Ibrahimi O.A., Kalinina J., Olsen S.K., Eliseenkova A.V., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Molecular and Cellular Biology 2007, 27:3417-3428.
48. Gong Y.Z., Everett E.T., Schwartz D.A., Norris J.S., Wilson F.A. Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:4741-4745.
49. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Molecular Cell 2000, 6:517-526.
50. Guo G.L., Lambert G., Negishi M., Ward J.M., Brewer H.B., Kliewer S.A., et al. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. The Journal of Biological Chemistry 2003, 278:45062-45071.
51. Hagenbuch B., Meier P.J. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. The Journal of Clinical Investigation 1994, 93:1326-1331.
52. Hagenbuch B., Stieger B., Foguet M., Lubbert H., Meier P.J. Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:10629-10633.
53. Halilbasic E., Fiorotto R., Fickert P., Marschall H.U., Moustafa T., Spirli C., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009, 49:1972-1981.
54. Han S., Li T., Ellis E., Strom S., Chiang J.Y. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Molecular Endocrinology 2010, 24:1151-1164.
55. Hanniman E.A., Lambert G., McCarthy T.C., Sinal C.J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. The Journal of Lipid Research 2005, 46:2595-2604.
56. Hirayama C., Irisa T. Serum cholesterol and bile acid in primary hepatoma. Clinica Chimica Acta; International Journal of Clinical Chemistry 1976, 71:21-25.
57. Hirschfield G.M., Mason A., Luketic V., Lindor K., Gordon S.C., Mayo M., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015, 148:751-761. e758.
58. Hofman M.K., Princen H.M., Zwinderman A.H., Jukema J.W. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clinical Science 2005, 108:539-545.
59. Hofmann A.F. Rifampicin and treatment of cholestatic pruritus. Gut 2002, 51:756-757.
60. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
61. Hussaini S.H., Pereira S.P., Murphy G.M., Dowling R.H. Deoxycholic acid influences cholesterol solubilization and microcrystal nucleation time in gallbladder bile. Hepatology 1995, 22:1735-1744.
62. Hylemon P.B., Melone P.D., Franklund C.V., Lund E., Bjorkhem I. Mechanism of intestinal 7 alpha-dehydroxylation of cholic acid: Evidence that allo-deoxycholic acid is an inducible side-product. The Journal of Lipid Research 1991, 32:89-96.
63. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metabolism 2005, 2:217-225.
64. Ishibashi S., Schwarz M., Frykman P.K., Herz J., Russell D.W. Disruption of cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. Journal of Biological Chemistry 1996, 271:18017-18023.
65. Ito S., Fujimori T., Furuya A., Satoh J., Nabeshima Y., Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. The Journal of Clinical Investigation 2005, 115:2202-2208.
66. Jiang Z.Y., Han T.Q., Suo G.J., Feng D.X., Chen S., Cai X.X., et al. Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease. World Journal of Gastroenterology 2004, 10:1508-1512.
67. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2004, 175:287-293.
68. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. The Journal of Biological Chemistry 2002, 277:2908-2915.
69. Katzenellenbogen M., Mizrahi L., Pappo O., Klopstock N., Olam D., Jacob-Hirsch J., et al. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Molecular Cancer Research: MCR 2007, 5:1159-1170.
70. Katzenellenbogen M., Pappo O., Barash H., Klopstock N., Mizrahi L., Olam D., et al. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Research 2006, 66:4001-4010.
71. Kauffman F.C. Sulfonation in pharmacology and toxicology. Drug Metabolism Reviews 2004, 36:823-843.
72. Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., et al. A G protein-coupled receptor responsive to bile acids. The Journal of Biological Chemistry 2003, 278:9435-9440.
73. Keitel V., Donner M., Winandy S., Kubitz R., Haussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochemical and Biophysical Research Communications 2008, 372:78-84.
74. Keitel V., Nies A.T., Brom M., Hummel-Eisenbeiss J., Spring H., Keppler D. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). American Journal of Physiology. Gastrointestinal and Liver Physiology 2003, 284:G165-G174.
75. Keitel V., Reinehr R., Gatsios P., Rupprecht C., Gorg B., Selbach O., et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007, 45:695-704.
76. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
77. Kitada H., Miyata M., Nakamura T., Tozawa A., Honma W., Shimada M., et al. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. The Journal of Biological Chemistry 2003, 278:17838-17844.
78. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocrine Reviews 2002, 23:687-702.
79. Kliewer S.A., Willson T.M. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. The Journal of Lipid Research 2002, 43:359-364.
80. Kullak-Ublick G.A., Stieger B., Hagenbuch B., Meier P.J. Hepatic transport of bile salts. Seminars in Liver Disease 2000, 20:273-292.
81. Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R., et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenetics and Genomics 2007, 17:47-60.
82. Leitersdorf E., Safadi R., Meiner V., Reshef A., Bjorkhem I., Friedlander Y., et al. Cerebrotendinous xanthomatosis in the Israeli Druze: Molecular genetics and phenotypic characteristics. The American Journal of Human Genetics 1994, 55:907-915.
83. Li T., Chiang J.Y. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. American Journal of Physiology. Gastrointestinal and Liver Physiology 2005, 288:G74-G84.
84. Li T., Chiang J.Y. Bile acid signaling in metabolic disease and drug therapy. Pharmacological Reviews 2014, 66:948-983.
85. Li T., Francl J.M., Boehme S., Ochoa A., Zhang Y., Klaassen C.D., et al. Glucose and insulin induction of bile acid synthesis: Mechanisms and implication in diabetes and obesity. The Journal of Biological Chemistry 2012, 287:1861-1873.
86. Li S., Hsu D.D., Li B., Luo X., Alderson N., Qiao L., et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metabolism 2014, 20:320-332.
87. Li T., Matozel M., Boehme S., Kong B., Nilsson L.M., Guo G., et al. Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 2011, 53:996-1006.
88. Li T., Owsley E., Matozel M., Hsu P., Novak C.M., Chiang J.Y. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010, 52:678-690.
89. Li-Hawkins J., Gafvels M., Olin M., Lund E.G., Andersson U., Schuster G., et al. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. The Journal of Clinical Investigation 2002, 110:1191-1200.
90. Limaye P.B., Bowen W.C., Orr A.V., Luo J., Tseng G.C., Michalopoulos G.K. Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 2008, 47:1702-1713.
91. Lin B.C., Wang M., Blackmore C., Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. The Journal of Biological Chemistry 2007, 282:27277-27284.
92. Lioudaki E., Ganotakis E.S., Mikhailidis D.P. Lipid lowering drugs and gallstones: A therapeutic option?. Current Pharmaceutical Design 2011, 17:3622-3631.
93. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. The Journal of Clinical Investigation 2003, 112:1678-1687.
94. Liu R., Zhao R., Zhou X., Liang X., Campbell D.J., Zhang X., et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 2014, 60:908-918.
95. Low-Beer T.S., Nutter S. Colonic bacterial activity, biliary cholesterol saturation, and pathogenesis of gallstones. Lancet 1978, 2:1063-1065.
96. Lu Y., Heydel J.M., Li X., Bratton S., Lindblom T., Radominska-Pandya A. Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: A potential role for a negative farnesoid X receptor response element. Drug Metabolism and Disposition 2005, 33:937-946.
97. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Molecular Cell 2000, 6:507-515.
98. Maeda Y., Nagatomo H., Kuroki N., Nagatomo J., Uchiyama F., Shimozono K., et al. Bile acid biosynthesis during liver regeneration: Enzyme activities of cholesterol 7alpha-hydroxylase and 3beta-hydroxy-delta5-C27-steroid dehydrogenase in rats. Annals of Clinical and Laboratory Science 2005, 35:323-328.
99. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
100. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
101. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
102. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83:835-839.
103. Marcus S.N., Heaton K.W. Deoxycholic acid and the pathogenesis of gall stones. Gut 1988, 29:522-533.
104. Maruyama T., Miyamoto Y., Nakamura T., Tamai Y., Okada H., Sugiyama E., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochemical and Biophysical Research Communications 2002, 298:714-719.
105. Maruyama T., Tanaka K., Suzuki J., Miyoshi H., Harada N., Nakamura T., et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. The Journal of Endocrinology 2006, 191:197-205.
106. Mason J.I., Boyd G.S. The suppressive effect of the catatoxic steroid, pregnenolone-16alpha-carbonitrile, on liver microsomal cholesterol-7alpha-hydroxlyase. Steroids 1978, 31:849-854.
107. McCarthy T.C., Li X., Sinal C.J. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. The Journal of Biological Chemistry 2005, 280:23232-23242.
108. McMahan R.H., Wang X.X., Cheng L.L., Krisko T., Smith M., El Kasmi K., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. The Journal of Biological Chemistry 2013, 288:11761-11770.
109. Mehendale H.M. Tissue repair: An important determinant of final outcome of toxicant-induced injury. Toxicologic Pathology 2005, 33:41-51.
110. Meier P.J. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. The American Journal of Physiology 1995, 269:G801-G812.
111. Meier P.J., Stieger B. Bile salt transporters. Annual Review of Physiology 2002, 64:635-661.
112. Mencarelli A., Renga B., Distrutti E., Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. American Journal of Physiology. Heart and Circulatory Physiology 2009, 296:H272-H281.
113. Meng Z., Wang Y., Wang L., Jin W., Liu N., Pan H., et al. FXR regulates liver repair after CCl4-induced toxic injury. Molecular Endocrinology 2010, 24:886-897.
114. Miao J., Fang S., Bae Y., Kemper J.K. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. The Journal of Biological Chemistry 2006, 281:14537-14546.
115. Michalopoulos G.K. Principles of liver regeneration and growth homeostasis. Comprehensive Physiology 2013, 3:485-513.
116. Miyake J.H., Doung X.D., Strauss W., Moore G.L., Castellani L.W., Curtiss L.K., et al. Increased production of apolipoprotein B-containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7alpha-hydroxylase. The Journal of Biological Chemistry 2001, 276:23304-23311.
117. Miyake J.H., Duong-Polk X.T., Taylor J.M., Du E.Z., Castellani L.W., Lusis A.J., et al. Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:121-126.
118. Miyata M., Kudo G., Lee Y.H., Yang T.J., Gelboin H.V., Fernandez-Salguero P., et al. Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene. The Journal of Biological Chemistry 1999, 274:23963-23968.
119. Myant N.B., Mitropoulos K.A. Cholesterol 7 alpha-hydroxylase. The Journal of Lipid Research 1977, 18:135-153.
120. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocrine Reviews 2005, 26:662-687.
121. Nakano K., Chijiiwa K., Okamoto S., Yamashita H., Kuroki S., Tanaka M. Hepatic cholesterol 7 alpha-hydroxylase activity and serum 7 alpha-hydroxy-cholesterol level during liver regeneration after partial hepatectomy in rats. European Surgical Research Europaische Chirurgische Forschung Recherches Chirurgicales Europeennes 1995, 27:389-395.
122. Neimark E., Chen F., Li X., Shneider B.L. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 2004, 40:149-156.
123. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
124. Nishida S., Ozeki J., Makishima M. Modulation of bile acid metabolism by 1alpha-hydroxyvitamin D3 administration in mice. Drug Metabolism and Disposition 2009, 37:2037-2044.
125. Noe J., Kullak-Ublick G.A., Jochum W., Stieger B., Kerb R., Haberl M., et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. Journal of Hepatology 2005, 43:536-543.
126. Ogura M., Nishida S., Ishizawa M., Sakurai K., Shimizu M., Matsuo S., et al. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. The Journal of Pharmacology and Experimental Therapeutics 2009, 328:564-570.
127. Otsuki M. Pathophysiological role of cholecystokinin in humans. Journal of Gastroenterology and Hepatology 2000, 15(Suppl.):D71-D83.
128. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
129. Pauli-Magnus C., Lang T., Meier Y., Zodan-Marin T., Jung D., Breymann C., et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004, 14:91-102.
130. Pean N., Doignon I., Garcin I., Besnard A., Julien B., Liu B., et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 2013, 58:1451-1460.
131. Pellicciari R., Costantino G., Camaioni E., Sadeghpour B.M., Entrena A., Willson T.M., et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. Journal of Medicinal Chemistry 2004, 47:4559-4569.
132. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. Journal of Medicinal Chemistry 2002, 45:3569-3572.
133. Pillot T., Ouzzine M., Fournel-Gigleux S., Lafaurie C., Radominska A., Burchell B., et al. Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4. The Journal of Biological Chemistry 1993, 268:25636-25642.
134. Pullinger C.R., Eng C., Salen G., Shefer S., Batta A.K., Erickson S.K., et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. The Journal of Clinical Investigation 2002, 110:109-117.
135. Rao A., Haywood J., Craddock A.L., Belinsky M.G., Kruh G.D., Dawson P.A. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:3891-3896.
136. Ridlon J.M., Hylemon P.B. A potential role for resistant starch fermentation in modulating colonic bacterial metabolism and colon cancer risk. Cancer Biology & Therapy 2006, 5:273-274.
137. Ridlon J.M., Kang D.J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. The Journal of Lipid Research 2006, 47:241-259.
138. Rosen H., Reshef A., Maeda N., Lippoldt A., Shpizen S., Triger L., et al. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. The Journal of Biological Chemistry 1998, 273:14805-14812.
139. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annual Review of Biochemistry 2003, 72:1370174.
140. Russell D.W., Setchell K.D. Bile acid biosynthesis. Biochemistry 1992, 31:4737-4749.
141. Saini S.P., Sonoda J., Xu L., Toma D., Uppal H., Mu Y., et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Molecular Pharmacology 2004, 65:292-300.
142. Sayin S.I., Wahlstrom A., Felin J., Jantti S., Marschall H.U., Bamberg K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metabolism 2013, 17:225-235.
143. Schaap F.G., van der Gaag N.A., Gouma D.J., Jansen P.L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49:1228-1235.
144. Schmidt D.R., Holmstrom S.R., Fon Tacer K., Bookout A.L., Kliewer S.A., Mangelsdorf D.J. Regulation of bile acid synthesis by fat-soluble vitamins A and D. The Journal of Biological Chemistry 2010, 285:14486-14494.
145. Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., Watkins P.B. Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metabolism and Disposition 2001, 29:1446-1453.
146. Shneider B.L., Dawson P.A., Christie D.M., Hardikar W., Wong M.H., Suchy F.J. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. The Journal of Clinical Investigation 1995, 95:745-754.
147. Slatis K., Gafvels M., Kannisto K., Ovchinnikova O., Paulsson-Berne G., Parini P., et al. Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. The Journal of Lipid Research 2010, 51:3289-3298.
148. Slijepcevic D., Kaufman C., Wichers C.G., Gilglioni E.H., Lempp F.A., Duijst S., et al. Impaired uptake of conjugated bile acids and Hepatitis B Virus preS1-binding in Na -taurocholate cotransporting polypeptide knockout mice. Hepatology 2015, [Epub ahead of print].
149. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
150. Song K.H., Li T., Owsley E., Strom S., Chiang J.Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009, 49:297-305.
151. Srivastava A. Progressive familial intrahepatic cholestasis. Journal of Clinical and Experimental Hepatology 2014, 4:25-36.
152. Stahlberg D. Effects of pregnenolone-16 alpha-carbonitrile on the metabolism of cholesterol in rat liver microsomes. Lipids 1995, 30:361-364.
153. Stanley L.A., Horsburgh B.C., Ross J., Scheer N., Wolf C.R. PXR and CAR: Nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metabolism Reviews 2006, 38:515-597.
154. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:3369-3374.
155. Stedman C.A., Liddle C., Coulter S.A., Sonoda J., Alvarez J.G., Moore D.D., et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:2063-2068.
156. Strautnieks S.S., Kagalwalla A.F., Tanner M.S., Knisely A.S., Bull L., Freimer N., et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. The American Journal of Human Genetics 1997, 61:630-633.
157. Studer E., Zhou X., Zhao R., Wang Y., Takabe K., Nagahashi M., et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 2012, 55:267-276.
158. Takikawa H., Otsuka H., Beppu T., Seyama Y., Yamakawa T. Serum concentrations of bile acid glucuronides in hepatobiliary diseases. Digestion 1983, 27:189-195.
159. Teixeira J., Gil G. Cloning, expression, and regulation of lithocholic acid 6 beta-hydroxylase. The Journal of Biological Chemistry 1991, 266:21030-21036.
160. Thummel K.E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Molecular Pharmacology 2001, 60:1399-1406.
161. Tomiyama Y., Takenaka K., Kodama T., Kawanaka M., Sasaki K., Nishina S., et al. Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis. Internal Medicine 2013, 52:1553-1559.
162. Trauner M., Boyer J.L. Bile salt transporters: Molecular characterization, function, and regulation. Physiological Reviews 2003, 83:633-671.
163. Trottier J., Verreault M., Grepper S., Monte D., Belanger J., Kaeding J., et al. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 2006, 44:1158-1170.
164. Uriarte I., Fernandez-Barrena M.G., Monte M.J., Latasa M.U., Chang H.C., Carotti S., et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 2013, 62:899-910.
165. Vacca M., Degirolamo C., Massafra V., Polimeno L., Mariani-Costantini R., Palasciano G., et al. Nuclear receptors in regenerating liver and hepatocellular carcinoma. Molecular and Cellular Endocrinology 2013, 368:108-119.
166. Vavassori P., Mencarelli A., Renga B., Distrutti E., Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. Journal of Immunology 2009, 183:6251-6261.
167. Vaz F.M., Paulusma C.C., Huidekoper H., de Ru M., Lim C., Koster J., et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype. Hepatology 2014, 61:260-267.
168. Von Dippe P., Amoui M., Alves C., Levy D. Na(+)-dependent bile acid transport by hepatocytes is mediated by a protein similar to microsomal epoxide hydrolase. The American Journal of Physiology 1993, 264:G528-G534.
169. von Dippe P., Amoui M., Stellwagen R.H., Levy D. The functional expression of sodium-dependent bile acid transport in Madin-Darby canine kidney cells transfected with the cDNA for microsomal epoxide hydrolase. The Journal of Biological Chemistry 1996, 271:18176-18180.
170. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M., Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48:1632-1643.
171. Wang Y.D., Chen W.D., Yu D., Forman B.M., Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 2011, 54:1421-1432.
172. Wang H., Venkatesh M., Li H., Goetz R., Mukherjee S., Biswas A., et al. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. The Journal of Clinical Investigation 2011, 121:3220-3232.
173. Wang C., Yang C., Chang J.Y., You P., Li Y., Jin C., et al. Hepatocyte FRS2alpha is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity. Current Molecular Medicine 2014, 14:703-711.
174. Weinshilboum R.M., Otterness D.M., Aksoy I.A., Wood T.C., Her C., Raftogianis R.B. Sulfation and sulfotransferases 1: Sulfotransferase molecular biology: cDNAs and genes. The FASEB Journal 1997, 11:3-14.
175. Wistuba W., Gnewuch C., Liebisch G., Schmitz G., Langmann T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World Journal of Gastroenterology 2007, 13:4230-4235.
176. Xia X., Francis H., Glaser S., Alpini G., LeSage G. Bile acid interactions with cholangiocytes. World Journal of Gastroenterology 2006, 12:3553-3563.
177. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Research 2007, 67:863-867.
178. Yeh H.Z., Schteingart C.D., Hagey L.R., Ton-Nu H.T., Bolder U., Gavrilkina M.A., et al. Effect of side chain length on biotransformation, hepatic transport, and choleretic properties of chenodeoxycholyl homologues in the rodent: Studies with dinorchenodeoxycholic acid, norchenodeoxycholic acid, and chenodeoxycholic acid. Hepatology 1997, 26:374-385.
179. Yokoyama Y., Nagino M., Nimura Y. Mechanism of impaired hepatic regeneration in cholestatic liver. Journal of Hepato-Biliary-Pancreatic Surgery 2007, 14:159-166.
180. Yoneno K., Hisamatsu T., Shimamura K., Kamada N., Ichikawa R., Kitazume M.T., et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 2013, 139:19-29.
181. Yoon Y.B., Hagey L.R., Hofmann A.F., Gurantz D., Michelotti E.L., Steinbach J.H. Effect of side-chain shortening on the physiologic properties of bile acids: Hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986, 90:837-852.
182. Zhang M., Chiang J.Y. Transcriptional regulation of the human sterol 12a-hydroxylase gene (CYP8B1): Roles of hepatocyte nuclear factor 4a (HNF4a) in mediating bile acid repression. The Journal of Biological Chemistry 2001, 276:41690-41699.
183. Zhang Q., He F., Kuruba R., Gao X., Wilson A., Li J., et al. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovascular Research 2008, 77:560-569.
184. Zhang L., Huang X., Meng Z., Dong B., Shiah S., Moore D.D., et al. Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration. Molecular Endocrinology 2009, 23:137-145.
185. Zhang L., Wang Y.D., Chen W.D., Wang X., Lou G., Liu N., et al. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine. Hepatology 2012, 56:2336-2343.
186. Zhang Y., Xu P., Park K., Choi Y., Moore D.D., Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 2008, 48:289-298.
187. Zhu Q.S., Xing W., Qian B., von Dippe P., Shneider B.L., Fox V.L., et al. Inhibition of human m-epoxide hydrolase gene expression in a case of hypercholanemia. Biochimica et Biophysica Acta 2003, 1638:208-216.
188. Zollner G., Trauner M. Mechanisms of cholestasis. Clinics in Liver Disease 2008, 12:1-26. vii.